AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials

May 18, 2016
Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III

AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …

sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

Novartis splits pharmaceuticals division into two business units

May 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …

opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …

michael_becker

Relmada Therapeutics appoints new chief financial officer

May 17, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing chief financial officer, relmada

Michael D. Becker has been appointed the new chief financial officer at Relmada Therapeutics. Becker joined the company in 2014 …

biogen_idec_hillerod_2008

Biogen signs $2 billion partnership deal with UPenn for gene therapies

May 17, 2016
Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …

actelion

Actelion granted EU approval for hypertension treatment

May 17, 2016
Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension

Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …

allergan

Allergan’s chronic eye disease treatment meets endpoints in pivotal trials

May 17, 2016
Manufacturing and Production, Sales and Marketing Allergan, FDA, chronic eye disease

Allergan has announced positive top line results from two pivotal late-stage trials for the first and only neurostimulation device for …

astrazeneca_plaque

AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial

May 17, 2016
Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial

UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …

dollars_medicines

Valeant announces expanded discounts for Nitropress and Isuprel

May 17, 2016
Manufacturing and Production, Sales and Marketing Isuprel, Nitropress, Valeant, discounts

Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) …

stocks3

Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …

pfizerbrussels

Pfizer to acquire Anacor in $5.2 billion deal

May 16, 2016
Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger

Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …

mylan_building

Mylan to buy Renaissance’s dermatology business for up to $1 billion

May 16, 2016
Research and Development, Sales and Marketing Mylan, generics, merger and acquisition

Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …

sanofi_hq__boetie_hall

Sanofi to replace entire Medivation board to drive sale, according to reports

May 16, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover

Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …

stocks1

Weekly Movers: Teva, Midatech, Allergan…

May 16, 2016
Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets

We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …

174571_1

Novartis says trials show its COPD drug more effective versus GSK’s Seretide

May 16, 2016
Research and Development, Sales and Marketing GSK, Novartis, drug trial, research

Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …

trials

Eisai granted additional indication for Lenvima in renal cell carcinoma

May 16, 2016
Sales and Marketing Eisai, additional indication, renal cell carcinoma

Eisai has announced that it has received approval from the US Food and Drug Administration (FDA) for an additional indication …

pfizerbrussels

Pfizer presents positive results in meningococcal disease late-stage trials

May 13, 2016
Research and Development Pfizer, Vaccine, late stage trials, meningococcal disease

Pfizer (NYSE: PFE) has announced results from two pivotal late-stage trials demonstrating the immunogenicity of Trumenba against invasive meningococcal B …

Clinical Trials Equipment Supplier Woodley Equipment Exhibiting at Outsourcing in Clinical Trials East Coast 2016

May 13, 2016

Woodley Equipment Company Limited is exhibiting at Outsourcing in Clinical Trials East Coast 2016.  The event is taking place on …

The Gateway to Local Adoption Series

Latest content